JP2021507895A5 - - Google Patents

Info

Publication number
JP2021507895A5
JP2021507895A5 JP2020533674A JP2020533674A JP2021507895A5 JP 2021507895 A5 JP2021507895 A5 JP 2021507895A5 JP 2020533674 A JP2020533674 A JP 2020533674A JP 2020533674 A JP2020533674 A JP 2020533674A JP 2021507895 A5 JP2021507895 A5 JP 2021507895A5
Authority
JP
Japan
Prior art keywords
methyl
oxy
amino
pyrazole
cyclohexane
Prior art date
Application number
JP2020533674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507895A (ja
JPWO2019126085A5 (https=
JP7301839B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/066110 external-priority patent/WO2019126085A1/en
Publication of JP2021507895A publication Critical patent/JP2021507895A/ja
Publication of JPWO2019126085A5 publication Critical patent/JPWO2019126085A5/ja
Publication of JP2021507895A5 publication Critical patent/JP2021507895A5/ja
Application granted granted Critical
Publication of JP7301839B2 publication Critical patent/JP7301839B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020533674A 2017-12-19 2018-12-18 Lpaアンタゴニストとしてのピラゾールn-連結のカルバモイルシクロヘキシル酸 Active JP7301839B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607541P 2017-12-19 2017-12-19
US62/607,541 2017-12-19
PCT/US2018/066110 WO2019126085A1 (en) 2017-12-19 2018-12-18 Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Publications (4)

Publication Number Publication Date
JP2021507895A JP2021507895A (ja) 2021-02-25
JPWO2019126085A5 JPWO2019126085A5 (https=) 2022-02-01
JP2021507895A5 true JP2021507895A5 (https=) 2022-02-01
JP7301839B2 JP7301839B2 (ja) 2023-07-03

Family

ID=65003575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020533674A Active JP7301839B2 (ja) 2017-12-19 2018-12-18 Lpaアンタゴニストとしてのピラゾールn-連結のカルバモイルシクロヘキシル酸

Country Status (14)

Country Link
US (1) US11384067B2 (https=)
EP (1) EP3728216B1 (https=)
JP (1) JP7301839B2 (https=)
KR (1) KR102698386B1 (https=)
CN (1) CN111699180B (https=)
AU (1) AU2018388482A1 (https=)
BR (1) BR112020011953A2 (https=)
CA (1) CA3085347A1 (https=)
EA (1) EA202091500A1 (https=)
ES (1) ES2962367T3 (https=)
IL (1) IL275361A (https=)
MX (1) MX2020005874A (https=)
SG (1) SG11202005701VA (https=)
WO (1) WO2019126085A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11447475B2 (en) * 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
KR102788997B1 (ko) 2018-09-18 2025-03-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
CN114456157A (zh) * 2020-11-10 2022-05-10 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
WO2022174882A1 (en) * 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
TWI853704B (zh) 2021-05-11 2024-08-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CN121773091A (zh) * 2023-09-08 2026-03-31 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途
CN117024409A (zh) * 2023-10-10 2023-11-10 药康众拓(北京)医药科技有限公司 氘代lpa1抑制剂化合物及其用途
WO2026061483A1 (zh) * 2024-09-19 2026-03-26 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US7432271B2 (en) * 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
EA201390821A1 (ru) 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
SG11201407229UA (en) * 2012-06-20 2014-12-30 Hoffmann La Roche Substituted pyrazole compounds as lpar antagonists
SG11201407228PA (en) 2012-06-20 2014-12-30 Hoffmann La Roche N-aryltriazole compounds as lpar antagonists
UA109868C2 (ru) 2012-06-20 2015-10-12 Ф. Хоффманн-Ля Рош Аг Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
US20170283400A1 (en) * 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
JP7212047B2 (ja) * 2017-12-19 2023-01-24 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
CN112041302B (zh) * 2017-12-19 2024-11-19 百时美施贵宝公司 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸
US11180488B2 (en) * 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Similar Documents

Publication Publication Date Title
JP2021507895A5 (https=)
JP2021507896A5 (https=)
HRP20211918T1 (hr) Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
JP2021508686A5 (https=)
JP2021506878A5 (https=)
JPWO2019126099A5 (https=)
JPWO2019126085A5 (https=)
JPWO2019126086A5 (https=)
US10941113B2 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
JP6824954B2 (ja) mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール
JP6218260B2 (ja) Jak阻害剤としてのアミノピリミジニル化合物
JP2021507900A5 (https=)
JP2021534124A5 (https=)
JP6824952B2 (ja) mIDH1阻害剤としての2−アリール−および2−アリールアルキル−ベンズイミダゾール
JP2020183410A5 (https=)
JP2017511794A5 (https=)
JPWO2020060915A5 (https=)
JP2020507589A5 (https=)
JP2019521984A5 (https=)
JP2019530669A5 (https=)
JP6783756B2 (ja) mIDH1阻害剤としてのベンゾイミダゾール−2−アミン
JP2010539110A5 (https=)
JP2017505790A (ja) mIDH1阻害剤としてのベンズイミダゾール−2−アミン
JP2005536475A5 (https=)
JP2015533782A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用